EUVIMEDEUVIMED entdecken
Crossref

Assessment of Cutaneous and Mucosal Direct Immunofluorescence Testing Practices in the US

Julia S Lehman, Anthony P Fernandez, Kristin M Leiferman, Nooshin K Brinster, Donna A Culton, Randie H Kim, Jeffrey P North, Benjamin K Stoff, Michael J Camilleri, Margaret M Cocks, Rosalie Elenitsas, Maxwell A Fung und 11 weitere

JAMA Dermatology · 01.07.2025 · 161 (7) · 747

DOI: 10.1001/jamadermatol.2025.0339 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Dermatology, erschienen am 01.07.2025. Verfasst von Julia S Lehman und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Mayo Clinic, Rochester, Minnesota. Hauptthemen laut MEDLINE: Skin Diseases, Dermatology. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 43 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Direct immunofluorescence (DIF) testing has been an important ancillary tool for the diagnosis of various inflammatory mucocutaneous conditions for more than 50 years. Current DIF test panels are based on historical clinical descriptions; few studies have rigorously addressed preanalytical, analytical, and/or postanalytical aspects, and even fewer have been replicated or validated. Recent unresolved key issues include whether DIF testing and test panels should be triaged or truncated based on clinical indication or histopathologic findings.

Objective

To assess levels of consensus regarding practical aspects of DIF testing among immunodermatology testing specialists in the US. Design, Setting, and Participants Using modified Delphi methods with a priori characterized criteria, a survey containing 54 statements pertaining to DIF testing was created and distributed to assess consensus. Statements not initially reaching consensus were discussed in 2 live virtual sessions, which were supplemented by relevant literature review and free-text survey comments. These statements were then reassessed in a second survey. Immunodermatology testing specialists in US academic institution–based and independent laboratories were invited based on serving as immunodermatology laboratory medical directors, authoring pertinent literature, or delivering relevant talks at major conferences or by referral. The first survey was conducted from January to February 2024, and the second survey was conducted from March to April 2024. Main Outcomes and Measures The primary measured outcome was degree of consensus for various DIF testing practice, including DIF testing triage by histopathology/dermatopathology findings and DIF testing panel tailored truncations by clinical indication.

Results

A total of 23 respondents to the survey invitation had a mean (SD) of 18.5 (11.1) years and median (range) of 20.0 (1.5-46.0) years in immunodermatology laboratory practice. Consensus was achieved for 46 of 54 statements (85.2%) in the initial survey and for an additional 4 statements in the second survey (50 of 54 [92.6%]). Strong consensus was found against tailored truncation of DIF panel based on the clinical indication in the first survey round. The general acceptability of triaging specimens for DIF testing based on histopathology findings remained without consensus after both surveys. Conclusions and Relevance Overall, participating US specialists in immunodermatology laboratory testing agreed on many practical aspects of DIF testing, including matters not queried previously. The findings also revealed areas of continued controversy and identified issues for prioritized future study.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Skin DiseasesDermatologyHumansUnited StatesFluorescent Antibody Technique, DirectConsensusDelphi TechniqueMucous MembraneSkin

Autor:innen und Institutionen

  • Department of Dermatology, Mayo Clinic, Rochester, Minnesota.
  • Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
  • Department of Dermatology and Pathology, Cleveland Clinic, Cleveland, Ohio.
  • Department of Dermatology, University of Utah Health, Salt Lake City.
  • Bridge Dermpath, Tarrytown, New York.
  • Department of Dermatology, University of North Carolina at Chapel Hill.

Zitieren

APA

Lehman, J. S., Fernandez, A. P., Leiferman, K. M., Brinster, N. K., Culton, D. A., Kim, R. H., North, J. P., Stoff, B. K., Camilleri, M. J., Cocks, M. M., Elenitsas, R., Fung, M. A., Grover, R. K., Jedrych, J. J., Kuechle, M. K., McNiff, J. M., Moshiri, A. S., Motaparthi, K., Murphy, M. J., …, & Bridges, A. G. (2025). Assessment of Cutaneous and Mucosal Direct Immunofluorescence Testing Practices in the US. JAMA Dermatology, 161(7), 747. https://doi.org/10.1001/jamadermatol.2025.0339

Vancouver

Lehman JS, Fernandez AP, Leiferman KM, Brinster NK, Culton DA, Kim RH, et al. Assessment of Cutaneous and Mucosal Direct Immunofluorescence Testing Practices in the US. JAMA Dermatology. 2025;161(7):747. doi:10.1001/jamadermatol.2025.0339

BibTeX
@article{Lehman2025,
  author = {Lehman, Julia S and Fernandez, Anthony P and Leiferman, Kristin M and Brinster, Nooshin K and Culton, Donna A and Kim, Randie H and North, Jeffrey P and Stoff, Benjamin K and Camilleri, Michael J and Cocks, Margaret M and Elenitsas, Rosalie and Fung, Maxwell A and Grover, Raminder K and Jedrych, Jaroslaw J and Kuechle, Melanie K and McNiff, Jennifer M and Moshiri, Ata S and Motaparthi, Kiran and Murphy, Michael J and Nousari, Carlos H and Shalin, Sara C and Zone, John J and Bridges, Alina G},
  title = {Assessment of Cutaneous and Mucosal Direct Immunofluorescence Testing Practices in the US},
  journal = {JAMA Dermatology},
  year = {2025},
  volume = {161},
  number = {7},
  pages = {747},
  doi = {10.1001/jamadermatol.2025.0339}
}
Kostenlos starten →